Abstract:BACKGROUND: Mitochondrial dysfunction and oxidative stress are closely associated with the pathogenesis of Parkinson's disease. Peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC-1α) is thought to play multiple roles in the regulation of mitochondrial biogenesis and cellular energy metabolism. We recently reported that altering PGC-1α gene expression modulates mitochondrial functions in N-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>) treated human SH-SY5Y neuroblastoma cells, possibly via the regulation of Estrogen-related receptor α (ERRα), nuclear respiratory factor 1 (NRF-1), nuclear respiratory factor 2 (NRF-2) and peroxisome proliferator-activated receptor γ (PPARγ) expression. In the present study, we aimed to further investigate the potential beneficial effects of PGC-1α in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated C57BL mice.METHODS: The overexpression or knockdown of the PGC-1α gene in the mouse model of dopaminergic neurotoxicity was performed using a stereotactic injection of lentivirus in MPTP-treated male C57BL/6 mice. Mice were randomly assigned to one of 6 groups (n=24 per group): normal saline (NS) intraperitoneal injection (i.p.) (con); MPTP i.p. (M); solvent of the lentivirus striatal injection (lentivirus control) + MPTP i.p. (LVcon+M); lentivirus striatal injection + MPTP i.p. (LV+M); LV-PGC-1α striatum injection + MPTP i.p. (LVPGC+M); and LV-PGC-1α-siRNA striatal injection + MPTP i.p. (LVsiRNA+M). Intraperitoneal injections of MPTP/NS were conducted two weeks after lentivirus injection.RESULTS: We found significant improvement in motor behavior and increases in tyrosine hydroxylase expression in the substantia nigra (SN) in the brains of mice in the LVPGC+M group. The opposite tendency was observed in those in the LVsiRNA+M group. The expression of superoxide dismutase (SOD) in the SN region was also consistent with the changes in PGC-1α expression. Electron microscopy showed an increasing trend in the mitochondrial density in the LVPGC+M group and a decreasing trend in the M and LVsiRNA+M groups compared to that in the controls.CONCLUSIONS: Our results indicated that PGC-1α rescues the effects of MPTP-induced mitochondrial dysfunction in C57BL mice.

PGC-1s in the Spotlight with Parkinson’s Disease

Deciphering the role of PGC-1α in neurological disorders: from mitochondrial dysfunction to synaptic failure

PGC−1α Promoter Methylation in Parkinson’s Disease

Peroxisom proliferator-activated receptor-γ coactivator-1α in neurodegenerative disorders: A promising therapeutic target

PGC-1α Regulation by FBXW7 Through a Novel Mechanism Linking Chaperone-Mediated Autophagy and the Ubiquitin-Proteasome System.

PGC-1α Sparks the Fire of Neuroprotection Against Neurodegenerative Disorders.

Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases

Expression of the Gene Coading for PGC-1α in Peripheral Blood Leukocytes and Related Gene Variants in Patients with Parkinson's Disease

Mitochondrial Effects of PGC-1alpha Silencing in MPP+ Treated Human SH-SY5Y Neuroblastoma Cells

Regulation of PGC-1α mediated by acetylation and phosphorylation in MPP+ induced cell model of Parkinson’s disease

Overexpression of PGC-1α Influences the Mitochondrial Unfolded Protein Response (mtupr) Induced by MPP+ in Human SH-SY5Y Neuroblastoma Cells

Beneficial effects of PGC-1α in the substantia nigra of a mouse model of MPTP-induced dopaminergic neurotoxicity

The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1α Regulates Rotenone-Induced Dopaminergic Neurotoxicity

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics

Post-translational Modification and Mitochondrial Function in Parkinson’s Disease

New insights into the complex role of mitochondria in Parkinson’s disease

Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond

Post-translational modification and mitochondrial function in Parkinson's disease

Targeting mitochondria with small molecules: A promising strategy for combating Parkinson's disease

Phosphoglycerate kinase is a central leverage point in Parkinson's disease–driven neuronal metabolic deficits

Genetic Deficiency of the Mitochondrial Protein PGAM5 Causes a Parkinson's-like Movement Disorder.